Clinical trial • Phase I • Oncology
Clinical trial in Hepatocellular carcinoma | Advanced or metastatic hepatocellular carcinoma
Phase I trial for Hepatocellular carcinoma | Advanced or metastatic hepatocellular carcinoma. 127 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Hepatocellular carcinoma | Advanced or metastatic hepatocellular carcinoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 28-03-2025
- First CTIS Authorization Date
- 27-06-2025
Trial design
Phase I trial across 3 sites in Italy.
- Target Sample Size
- 127
Recruitment
- Planned Sample Size
- 127
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 127
Italy
- Earliest CTIS Part Ii Submission Date
- 13-06-2025
- Latest Decision Or Authorization Date
- 28-04-2026
- Processing Time Days
- 319
- Number Of Sites
- 3
- Number Of Participants
- 31
Sites
- Site Name
- Humanitas Mirasole S.p.A.
- Department Name
- Operative unit of Oncology and Hematology
- Principal Investigator Name
- Armando Santoro
- Contact Person Name
- Armando Santoro
- Contact Person Email
- armando.santoro@cancercenter.humanitas.it
- Site Name
- Ospedale San Raffaele S.r.l.
- Department Name
- U.O. Oncologia Medica unità di Fase I
- Principal Investigator Name
- Gianluca Del Conte
- Contact Person Name
- Gianluca Del Conte
- Contact Person Email
- delconte.gianluca@hsr.it
- Site Name
- Centro Ricerche Cliniche Di Verona S.r.l.
- Department Name
- Oncology Unit
- Principal Investigator Name
- Michele Milella
- Contact Person Name
- Michele Milella
- Contact Person Email
- Michele.milella@univr.it
Sponsor
Primary sponsor
- Full Name
- Alnylam Pharmaceuticals Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)